Molecular residual disease (MRD) testing and circulating tumor DNA (ctDNA) diagnostics are moving into routine oncology practice, and the companies commercializing them need names clinicians recognize. This category covers MRD and ctDNA name families, cancer-diagnostics platforms and oncology-care brands, with matching .com/.online pairs for several names. A seven-domain MRD & ctDNA bundle is available at a package price. Every name is trademark-screened before listing.
14 domains · €990–€8,000 · Buy now via Sedo escrow, or make an offer.
Circulating tumor DNA domain for liquid biopsy, cancer screening, minimal residual disease monitoring, and precision oncology.
ctDNA monitoring domain for cancer recurrence surveillance, treatment response tracking, and liquid biopsy services.
Bispecific antibody oncology domain — dual-target immunotherapy, T-cell engagers, and cancer treatment innovation.
Cancer patient-reported outcomes domain — oncology PROMs, survivorship tracking, and quality of life measurement.
Minimal residual disease platform domain — MRD testing, cancer monitoring, and molecular diagnostics infrastructure.
liquidmrd.com — premium .com fusing liquid biopsy and MRD (minimal residual disease), the two most valuable categories in precision oncology 2026. Natera Signatera, Guardant Reveal, Exact Sciences Oncodetect, NeoGenomics RaDaR all scaling in this space. Ideal for ctDNA MRD diagnostic startups, AI-first cancer surveillance platforms, liquid-biopsy labs, and pharma companion diagnostics. Exact-match, category-authority, investor-ready.
MRD cancer test domain for minimal residual disease testing, precision oncology diagnostics, and cancer monitoring.
Specialty TLD for oncology, immuno-oncology, precision oncology, and tumor research platforms.
Professional B2B .com for molecular surveillance platforms — NCCN and ASCO-adopted terminology for longitudinal ctDNA and MRD monitoring in oncology.
Domain for cancer recurrence monitoring and ctDNA surveillance — fits precision oncology startups and oncology AI products building longitudinal recurrence-detection workflows.
MRD-negative status domain — oncology reporting, remission communication, and precision cancer care.
Cancer care technology for oncology platforms, treatment coordination, and survivorship programs.
Online brand for MRD testing education, oncology outreach, and diagnostic lead generation.
Online brand for MRD-negative education, oncology communication, and clinical information.